PMID- 38274236
OWN - NLM
STAT- MEDLINE
DCOM- 20240129
LR  - 20240306
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - Combined effects of sodium-glucose cotransporter 2 inhibitor and angiotensin 
      receptor-neprilysin inhibitor on renal function in cardiovascular disease 
      patients with type 2 diabetes mellitus: a retrospective cohort study.
PG  - 1326611
LID - 10.3389/fendo.2023.1326611 [doi]
LID - 1326611
AB  - BACKGROUND: Angiotensin receptor/neprilysin inhibitor (ARNI) and sodium-glucose 
      cotransporter 2 inhibitor (SGLT2i) have shown a significant protective role 
      against cardiovascular diseases and type 2 diabetes mellitus (T2DM), and there is 
      a growing proportion of patients who are undergoing combined therapy with the two 
      drugs. However, the effect of this combination treatment on renal function has 
      not yet been determined. METHODS: This study included 539 patients who were 
      diagnosed with cardiovascular disease combined with T2DM. According to the use of 
      SGLT2i and ARNI, patients were divided into the combination treatment group, 
      SGLT2i group, ARNI group and control group. Primary outcomes were serum 
      creatinine (Scr) and estimated glomerular filtration rate (eGFR) changes in the 
      6th month and 12th month. RESULTS: In the ARNI group, no significant changes in 
      Scr or eGFR were observed during the follow-up period, while the above indicators 
      showed a trend of deterioration in the other three groups. The univariate 
      analysis results showed that at 6 months of follow-up, the renal function 
      indicators of patients treated with ARNI (either alone or in combination) were 
      better than those treated with SGLT2i alone. After 12 months of follow-up, the 
      Scr results were the same as before, while the difference in eGFR between groups 
      disappeared. After multivariate analysis, in terms of delaying the progression of 
      Scr, the ARNI group was superior to the other groups at the end of follow-up. No 
      significant difference in eGFR was observed between groups during follow-up. 
      CONCLUSION: In patients with cardiovascular disease and T2DM, combination therapy 
      with ARNI and SGLT2i did not show an advantage over monotherapy in delaying renal 
      insufficiency progression, and renal function seems to be better preserved in 
      patients treated with ARNI alone. CLINICAL TRIAL REGISTRATION: 
      clinicaltrials.gov, identifier NCT05922852.
CI  - Copyright (c) 2024 Xu, Chen, Zhang and Zhu.
FAU - Xu, Ling
AU  - Xu L
AD  - Department of Cardiology, Peking University Third Hospital, NHC Key, Laboratory 
      of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, 
      Beijing, China.
FAU - Chen, Bo
AU  - Chen B
AD  - Department of Cardiology, Peking University Third Hospital, NHC Key, Laboratory 
      of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, 
      Beijing, China.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Research Center of Clinical Epidemiology, Peking University Third Hospital, 
      Peking University, Beijing, China.
FAU - Zhu, Dan
AU  - Zhu D
AD  - Department of Cardiology, Peking University Third Hospital, NHC Key, Laboratory 
      of Cardiovascular Molecular Biology and Regulatory Peptides, Peking University, 
      Beijing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT05922852
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20240111
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - EC 3.4.24.11 (Neprilysin)
RN  - 0 (Receptors, Angiotensin)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Cardiovascular Diseases
MH  - Neprilysin
MH  - Retrospective Studies
MH  - Kidney
MH  - Receptors, Angiotensin/therapeutic use
MH  - Glucose/therapeutic use
MH  - Sodium
PMC - PMC10808758
OTO - NOTNLM
OT  - ARNI
OT  - SGLT-2 inhibitor
OT  - cardiovascular disease
OT  - combination treatment
OT  - diabetes
OT  - renal function
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/26 06:43
MHDA- 2024/01/29 06:43
PMCR- 2023/01/01
CRDT- 2024/01/26 03:50
PHST- 2023/10/23 00:00 [received]
PHST- 2023/12/20 00:00 [accepted]
PHST- 2024/01/29 06:43 [medline]
PHST- 2024/01/26 06:43 [pubmed]
PHST- 2024/01/26 03:50 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1326611 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2024 Jan 11;14:1326611. doi: 
      10.3389/fendo.2023.1326611. eCollection 2023.